Metabolic · In Clinical Trials
Retatrutide
No lawful US pathway
01 · Overview
An investigational once-weekly triple hormone receptor agonist targeting GIP, GLP-1, and glucagon receptors, not yet FDA approved. The glucagon receptor component is intended to add increased energy expenditure and liver fat mobilization to the incretin-mediated appetite suppression and glucose control.
It is being studied for obesity, type 2 diabetes, knee osteoarthritis and obstructive sleep apnea (PMID 42810372).
02 · Research summary & key findings
A phase 2 trial (2023) showed mean weight reductions of up to 24.2% at 48 weeks versus 2.1% with placebo (PMID 37366315), and a substudy found liver fat reductions of up to 82% (PMID 38858523). In phase 3 TRIUMPH-1, weight fell up to 25.0% at 80 weeks versus 3.9% with placebo (PMID 42814954); TRIUMPH-2 in type 2 diabetes showed up to 18.8% (PMID 42810372).
03 · Regulatory status
Retatrutide is currently undergoing clinical trials. It is not yet FDA-approved and is available only through clinical research settings or investigational protocols.
No lawful pathway today
Retatrutide is not FDA-approved and does not currently have a lawful prescription or compounding pathway in the United States, so we do not sell it and will not book a consultation for it. That can change: in 2026 FDA began reviewing several peptides for compounding. If you are working on the goal it is studied for, a licensed clinician can tell you what is lawfully available, which may be something else.
See the 13 FDA-approved compounds in Metabolic
Tell me if the status changes
One email, only if this compound's regulatory standing actually moves. Not a newsletter, not a sales sequence.
Looking for a lawful, clinician-prescribed option for metabolic health and weight?
Retatrutide is still in clinical trials, is not FDA-approved, and has no lawful US compounding pathway, so we do not offer it and no clinician we work with will prescribe it. Products sold online as “research chemicals” are not made or tested to the standards required of medicines. If you are working on metabolic health and weight, a licensed clinician can tell you at a free consultation whether an FDA-approved or lawfully compounded treatment fits you, or whether nothing does.
Explore lawful options (free intake)About 3 minutes. If a protocol is prescribed through our provider, we earn 10% of the sale. See the receipts.
04 · Administration routes
- Subcutaneous injection (weekly)
References
- [1]Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial N Engl J Med, 2023. PMID 37366315
- [2]Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial Nat Med, 2024. PMID 38858523
- [3]Retatrutide in adults with obesity and type 2 diabetes (TRIUMPH-2): a double-blind, parallel-group, randomised, placebo-controlled, phase 3 trial Lancet, 2026. PMID 42810372
- [4]Retatrutide, a Triple Hormone Receptor Agonist, for Treatment of Obesity N Engl J Med, 2026. PMID 42814954
Primary literature
- PubMed: "Retatrutide"
Peer-reviewed literature indexed by the National Library of Medicine.
- ClinicalTrials.gov: "Retatrutide"
Registered interventional and observational studies, including status and phase.
- PubChem: "Retatrutide"
Chemical structure, molecular properties, and bioactivity data.
Related peptides in Metabolic
Disclaimer: This information is provided for educational and research purposes only. It is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any peptide therapy. The Peptide Association does not endorse or recommend any specific treatment protocol. See our editorial policy for how this content is produced and reviewed. Clinicians: join the network.